Followed Journals
Journal you Follow: 0
 
Sign Up to follow journals, search in your chosen journals and, optionally, receive Email Alerts when new issues of your Followed Journals are published.
Already have an account? Sign In to see the journals you follow.
Similar Journals
Journal Cover
Blood
Journal Prestige (SJR): 6.434
Citation Impact (citeScore): 7
Number of Followers: 409  
 
  Hybrid Journal Hybrid journal (It can contain Open Access articles)
ISSN (Print) 0006-4971 - ISSN (Online) 1528-0020
Published by American Society of Hematology Homepage  [1 journal]
  • "> Introduction to a review series on small-molecule targeted therapies
           for lymphoid malignancies

    • Free pre-print version: Loading...

      Authors: Roberts; Andrew, Stevenson, Freda
      Abstract: Targeted therapies have been central to improvements in the treatment of hematologic malignancies. We present a review series edited by Andrew Roberts and Freda Stevenson focusing on Bruton tyrosine kinase inhibitors, phosphoinositide 3-kinase inhibitors, and BH3 mimetics and their role in the treatment of chronic lymphocytic leukemia, non-Hodgkin lymphomas and acute myeloid leukemia.
      PubDate: 2021-10-05T23:20:50-05:00
      Issue No: Vol. 138, No. 13 (2021)
       
  • "> CEBPA bZip mutations: just a single shot

    • Free pre-print version: Loading...

      Authors: Sierra; Jorge, Nomdedeu, Josep
      PubDate: 2021-10-05T23:20:50-05:00
      Issue No: Vol. 138, No. 13 (2021)
       
  • "> Heme: driver of erythrocyte elimination

    • Free pre-print version: Loading...

      Authors: Dimitrov; Jordan, Roumenina, Lubka
      PubDate: 2021-10-05T23:20:50-05:00
      Issue No: Vol. 138, No. 13 (2021)
       
  • "> Increased oxygen affinity: to have and to hold

    • Free pre-print version: Loading...

      Authors: Quinn; Charles, Ware, Russell
      PubDate: 2021-10-05T23:20:50-05:00
      Issue No: Vol. 138, No. 13 (2021)
       
  • "> A long-half-life, high-affinity P-selectin inhibitor

    • Free pre-print version: Loading...

      Authors: Gross; Peter
      PubDate: 2021-10-05T23:20:50-05:00
      Issue No: Vol. 138, No. 13 (2021)
       
  • "> Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of
           their success story in lymphoid malignancies

    • Free pre-print version: Loading...

      Authors: Stephens; Deborah, Byrd, John
      PubDate: 2021-10-05T23:20:50-05:00
      Issue No: Vol. 138, No. 13 (2021)
       
  • "> Targeting B-cell receptor and PI3K signaling in diffuse large B-cell
           lymphoma

    • Free pre-print version: Loading...

      Authors: Xu; Wendan, Berning, Philipp, Lenz, Georg
      PubDate: 2021-10-05T23:20:50-05:00
      Issue No: Vol. 138, No. 13 (2021)
       
  • "> BCL2 and MCL1 inhibitors for hematologic malignancies

    • Free pre-print version: Loading...

      Authors: Roberts; Andrew, Wei, Andrew, Huang, David
      PubDate: 2021-10-05T23:20:50-05:00
      Issue No: Vol. 138, No. 13 (2021)
       
  • "> CEBPA-bZip mutations are associated with favorable prognosis in de novo
           AML: a report from the Children's Oncology Group

    • Free pre-print version: Loading...

      Authors: Tarlock; Katherine, Lamble, Adam, Wang, Yi-Cheng, Gerbing, Robert, Ries, Rhonda, Loken, Michael, Brodersen, Lisa, Pardo, Laura, Leonti, Amanda, Smith, Jenny, Hylkema, Tiffany, Woods, William, Cooper, Todd, Kolb, E., Gamis, Alan, Aplenc, Richard, Alonzo, Todd, Meshinchi, Soheil
      Abstract: Patients with biallelic mutations in CEBPA have improved survival, and this genotype is classified as favorable in the European Leukemia Net and National Comprehensive Cancer Network guidelines. In a study of over 3000 patients in Children's Oncology Group (COG) studies of acute myeloid leukemia (AML) combining clinical and genetic analysis, Tarlock et al identify monoallelic mutations in the C-terminal basic leucine zipper (bZip) of CEBPA to be prognostic. They report that single bZip and biallelic CEBPA mutations have identical prognoses, suggesting that in young patients with AML, these entities should be considered equally favorable.
      PubDate: 2021-10-05T23:20:50-05:00
      Issue No: Vol. 138, No. 13 (2021)
       
  • child"> CEBPA bZip mutations: just a single shot

    • Free pre-print version: Loading...

      Authors: Sierra; Jorge, Nomdedeu, Josep
      PubDate: 2021-10-05T23:20:50-05:00
      Issue No: Vol. 138, No. 13 (2021)
       
  • "> Tumor suppressor function of Gata2 in acute promyelocytic leukemia

    • Free pre-print version: Loading...

      Authors: Katerndahl; Casey, Rogers, Olivia, Day, Ryan, Cai, Michelle, Rooney, Timothy, Helton, Nichole, Hoock, Mieke, Ramakrishnan, Sai, Srivatsan, Sridhar, Wartman, Lukas, Miller, Christopher, Ley, Timothy
      Abstract: Katerndahl et al investigate genes dysregulated by PML-RARA in mouse and human cells and demonstrate that GATA2 is highly expressed in preleukemic cells expressing PML-RARA; furthermore, somatic GATA2 mutations occur during progression of acute promyelocytic leukemia (APL). They demonstrate that GATA2 knockout increases APL penetrance and decreases latency, while restoration of GATA2 expression suppresses penetrance and increases latency. These studies suggest a role for GATA2 as a tumor suppressor in AML development.
      PubDate: 2021-10-05T23:20:50-05:00
      Issue No: Vol. 138, No. 13 (2021)
       
  • "> Type I interferon is induced by hemolysis and drives antibody-mediated
           erythrophagocytosis in sickle cell disease

    • Free pre-print version: Loading...

      Authors: Liu; Yunfeng, Pal, Mouli, Bao, Weili, Shi, Patricia, Lobo, Cheryl, An, Xiuli, Manwani, Deepa, Zhong, Hui, Yazdanbakhsh, Karina
      Abstract: Hemolytic disorders such as sickle cell disease (SCD) are associated with the release of free heme. Liu and colleagues demonstrate that in SCD, free heme drives increased levels of type I interferon (IFN-I) by monocyte/macrophages. Increased IFN-I recruits monocyte recruitment to the liver, where it increases antibody-mediated erythrophagocytosis. This may explain the increased risk for delayed hemolytic transfusion reactions and hyperhemolysis in patients with SCD.
      PubDate: 2021-10-05T23:20:50-05:00
      Issue No: Vol. 138, No. 13 (2021)
       
  • child"> Heme: driver of erythrocyte elimination

    • Free pre-print version: Loading...

      Authors: Dimitrov; Jordan, Roumenina, Lubka
      PubDate: 2021-10-05T23:20:50-05:00
      Issue No: Vol. 138, No. 13 (2021)
       
  • "> Treatment of sickle cell disease by increasing oxygen affinity of
           hemoglobin

    • Free pre-print version: Loading...

      Authors: Henry; Eric, Metaferia, Belhu, Li, Quan, Harper, Julia, Best, Robert, Glass, Kristen, Cellmer, Troy, Dunkelberger, Emily, Conrey, Anna, Thein, Swee, Bunn, H., Eaton, William
      Abstract: Voxelotor, a drug that increases the oxygen affinity of hemoglobin, reduces red cell sickling and increases hemoglobin levels in patients with SCD; however, it has not been shown to decrease SCD crises. In elegant studies using a novel in vitro sickling assay, Henry et al demonstrate that decreased sickling induced by voxelotor is balanced by a decrease in oxygen delivery that may offset any benefit of improved red cell survival.
      PubDate: 2021-10-05T23:20:50-05:00
      Issue No: Vol. 138, No. 13 (2021)
       
  • child"> Increased oxygen affinity: to have and to hold

    • Free pre-print version: Loading...

      Authors: Quinn; Charles, Ware, Russell
      PubDate: 2021-10-05T23:20:50-05:00
      Issue No: Vol. 138, No. 13 (2021)
       
  • "> A PSGL-1 glycomimetic reduces thrombus burden without affecting
           hemostasis

    • Free pre-print version: Loading...

      Authors: Wong; Daniel, Park, Diane, Park, Simon, Haller, Carolyn, Chen, Jiaxuan, Dai, Erbin, Liu, Liying, Mandhapati, Appi, Eradi, Pradheep, Dhakal, Bibek, Wever, Walter, Hanes, Melinda, Sun, Lijun, Cummings, Richard, Chaikof, Elliot
      Abstract: P-selectin expressed on the surface of activated platelets and endothelium binds PSGL-1 expressed on leukocytes. Wong et al describe a novel pegylated P-selectin inhibitor, P-G6, that blocks platelet-leukocyte and endothelium-leukocyte interactions. PG6 reduces thrombosis in a murine model of thrombosis without disrupting hemostasis, positioning it as a promising candidate for clinical studies for prevention of venous thrombosis.
      PubDate: 2021-10-05T23:20:50-05:00
      Issue No: Vol. 138, No. 13 (2021)
       
  • child"> A long-half-life, high-affinity P-selectin inhibitor

    • Free pre-print version: Loading...

      Authors: Gross; Peter
      PubDate: 2021-10-05T23:20:50-05:00
      Issue No: Vol. 138, No. 13 (2021)
       
  • "> Immune evasion in primary testicular and central nervous system
           lymphomas: HLA loss rather than 9p24.1/PD-L1/PD-L2 alterations

    • Free pre-print version: Loading...

      Authors: Minderman; Marthe, Amir, Avital, Kraan, Willem, Schilder-Tol, Esther, Oud, Monique, Scheepstra, Cornelis, Noorduyn, Arnold, Kluin, Philip, Kersten, Marie, Spaargaren, Marcel, Pals, Steven
      PubDate: 2021-10-05T23:20:50-05:00
      Issue No: Vol. 138, No. 13 (2021)
       
  • "> Leukemic presentation of a highly aggressive ALK-negative anaplastic
           large cell lymphoma

    • Free pre-print version: Loading...

      Authors: Xu; Danmei, Naresh, Kikkeri
      PubDate: 2021-10-05T23:20:50-05:00
      Issue No: Vol. 138, No. 13 (2021)
       
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
 


Your IP address: 3.237.16.210
 
Home (Search)
API
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-